Send to

Choose Destination
Am J Hematol. 2018 Jun;93(6):786-793. doi: 10.1002/ajh.25099. Epub 2018 Apr 16.

CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.

Jin CH1,2, Li Y1,2, Xia J2, Li Y1,2, Chen M1,2, Hu Z1, Mapara MY2, Li W1, Yang YG1,2.

Author information

The First Hospital, Institute of Immunology and International Center of Future Science of Jilin University, Changchun, China.
Columbia Center for Translational Immunology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York.


Persistent low levels of disease in bone marrow, an immunoprivileged tissue, are responsible for relapse following allogeneic hematopoietic cell transplantation. Using mouse models carrying primary human acute lymphoblast leukemia derived from MLL-AF9-overexpressing human hematopoietic stem cells, we demonstrate that allogeneic lymphocyte infusion (ALI)-mediated graft-vs.-leukemia effects selectively spare leukemia cells in the bone marrow. The resistance of leukemia cells to ALI within bone marrow is due to the immunosuppressive status of the tissue, as ALI achieved a significantly increased complete remission rate when leukemia cells were dislodged from bone marrow by treatment with a CXCR4 antagonist AMD3100. Adoptive transfer experiments confirmed that the frequency of leukemia-initiating cells in bone marrow was significantly decreased in the recipients treated with ALI plus AMD3100 compared to those receiving ALI only. These findings indicate that the immunoprivileged nature of bone marrow is largely responsible for relapse after immunotherapies, and that treatment with AMD3100 may offer a clinically-practical approach to improving the outcome of adoptive allogeneic cell therapy.

[Available on 2019-06-01]
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center